Clinical trials: Hypertrophic Cardiomyopathies
Hypertrophic Cardiomyopathy
Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
Fibrosis, myocardial deformation and biomarkers in hypertrophic cardiomyopathy (HCM)
- Trial name
- HCM (NCT02922517)
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Nantes University Hospital
Hypertrophic Obstructive Cardiomyopathy
Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test
The objectives of this study are to determine if the left ventricle outflow tract (LVOT) gradients may be reproduced with dobutamine (DBT) provocation test in obstructive HCM patients under general anesthesia and to analyze the…
- Trial name
- NCT05025644
- Testing
- Pre and post-CPB Drug: Dobutamine Hydrochloride, Post-CPB Drug: Dobutamine Hydrochloride
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Myocardial Bridging, Obstructive Hypertrophic Cardiomyopathy
Myocardial Bridging in Obstructive Hypertrophic Cardiomyopathy
This study investigated the impact of myocardial bridging (MB) and its characteristics on preoperative atrial fibrillation and survival in patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Conditions
- Myocardial Bridging, Obstructive Hypertrophic Cardiomyopathy, Atrial Fibrillation (AF)
- Trial name
- MB in oHCM (NCT06598995)
- Testing
- Coronary artery bypass grafting or unroofing
- Where
- China
- Volunteers
- 968 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Hypertrophic Cardiomyopathy
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death.
- Trial name
- NCT02234336
- Testing
- Noncontrast echocardiography, Contrast Echocardiography, Cardiac magnetic resonance imaging
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Mayo Clinic
Hypertrophic Cardiomyopathy
A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
This study will compare two treatments: pacemaker implantation and percutaneous transluminal septal ablation (PTSA) for patients with hypertrophic cardiomyopathy (HCM), a condition in which the heart muscle thickens and obstructs…
- Trial name
- NCT00001894
- Testing
- pacemaker implantation, percutaneous transluminal septal ablation (PTSA)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Obstructive Hypertrophic Cardiomyopathy
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Researchers are looking for a better way to treat Japanese people who have symptomatic obstructive hypertrophic cardiomyopathy (symptomatic oHCM).
- Trial name
- CAMELLIA-HCM (NCT07023341)
- Testing
- BAY3723113
- Where
- 23 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Bayer
Hypertrophic Cardiomyopathy (HCM)
Aficamten and Patient-Reported Outcomes in Real-World nHCM
This multicenter, prospective, observational, real-world clinical study aims to evaluate the efficacy and safety of Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) by prospectively…
- Trial name
- CAMPHOR-HCM (NCT07846176)
- Testing
- receiving aficamten
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cardiac Glycogenosis, Cardiomyopathy
ATR 1072 in Participants With PRKAG2 Syndrome
ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug.
- Conditions
- Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome
- Trial name
- NCT07738107
- Testing
- ATR 1072
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Atrium Therapeutics
Coronary Cicrovascular Dysfunction, Hypertrophic Cardiomyopathy Patients
Prognostic Significance of CMD Assessed by IMR in HCM Patients
The index of microcirculatory resistance (IMR) serves as an indicator of coronary microvascular dysfunction (CMD) with significant prognostic value in various clinical conditions.
- Trial name
- caIMR-HCM (NCT06190704)
- Testing
- caIMR
- Volunteers
- 191 people
- Sponsor
- Ya-Wei Xu
HOCM, Hypertrophic Obstructive Cardiomyopathy
CRyo-Ablation to Treat Patients With HOCM.
The purpose of the study is to perform endocardial catheter CRyo-Ablation to relieve the LVOT obstruction in patients with Hypertrophic Obstructive Cardiomyopathy.
- Trial name
- CRASH (NCT01875016)
- Testing
- CRyo-Ablation to Treat HOCM.
- Volunteers
- 15 people
- Sponsor
- Shaare Zedek Medical Center
Hypertrophic Cardiomyopathy (HCM), Left Ventricular Hypertrophy
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic…
- Trial name
- NCT07263204
- Where
- China
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hypertrophic Cardiomyopathy
A Biomarker and MRI Study on Troponin Release After Exercise in Hypertrophic Cardiomyopathy
Study population: 1) mutation carriers without the hypertrophic phenotype (pre-clinical Hypertrophic Cardiomyopathy (HCM)) and in 2) patients with clinically overt HCM (clinical HCM).
- Trial name
- BE STRONG HCM (NCT01559714)
- Where
- Netherlands
- Volunteers
- 81 people
- Sponsor
- Heartcenter, University Medical Center St. Radboud
Coronary Artery Disease, Heart Failure
Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD.
- Conditions
- Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy, Congenital Heart Disease
- Trial name
- SE2030 (NCT05081115)
- Testing
- ABCDE-Stress Echo, SE diastolic assessment, SE Right ventricular function assessment
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- Fatebenefratelli Hospital
Angina, Unstable, Myocardial Infarction
Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
This study will examine the relationship between certain measures of heart function and exercise capacity in patients with hypertrophic cardiomyopathy (HCM).
- Conditions
- Angina, Unstable, Myocardial Infarction, Ischemic Heart Disease
- Trial name
- NCT00354328
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Obstructive Cardiomyopathy, Stereotactic Body Radiotherapy
Safety and Efficacy of Stereotactic Body Radiotherapy in the Treatment of Hypertrophic Obstructive Cardiomyopathy
This study is designed to rigorously evaluate the safety and effectiveness of Stereotactic Body Radiotherapy (SBRT) as an innovative, non-invasive treatment for Hypertrophic Obstructive Cardiomyopathy (HOCM).
- Trial name
- SAFECARE (NCT06167876)
- Testing
- Stereotactic Body Radiotherapy (SBRT) Treatment
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Second Xiangya Hospital of Central South University
Hypertrophic Cardiomyopathy
Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy
Hypertrophic cardiomyopathy (HCM) is a common heart condition in which the heart muscle becomes abnormally thick. In non-obstructive HCM, blood flow out of the heart is not blocked, but many patients still experience chest pain…
- Trial name
- COSMIC-HCM (NCT07865364)
- Testing
- Coronary sinus reducer
- Where
- 8 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Septal Hypertrophy, Obstructive Hypertrophic Cardiomyopathy
Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
In some patients, septal hypertrophy extends more distally, from the subaortic portion of the septum to the midventricular portion.
- Trial name
- NCT05726799
- Testing
- Cryo myectomy, Myectomy
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Michele De Bonis
Hypertrophic Cardiomyopathy
Comparison of Data Obtained by Echocardiography and Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy
Compare data (structural and functional) obtained by transthoracic rest echocardiography and magnetic resonance imaging (with gadolinium) in 30 patients with hypertrophic cardiomyopathy
- Trial name
- NCT00315783
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypertrophic Cardiomyopathy
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and…
- Trial name
- VANISH (NCT01912534)
- Testing
- Valsartan
- Where
- 15 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Carelon Research
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiomyopathy is a disease of the heart muscle. It is rare, but it can be serious. Cardiomyopathy in children can result in death, disability, heart transplantation or serious heart rhythm disorders.
- Trial name
- NCT01873976
- Where
- 13 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- Wayne State University